Early Evidence of Neratinib Benefit in HER2-Positive Metastatic Cervical Cancer
Single-agent neratinib was associated with durable responses in a subcohort of women in the SUMMIT trial.
Single-agent neratinib was associated with durable responses in a subcohort of women in the SUMMIT trial.
High expression of indoleamine 2.3-dioxygenase pathway genes correlated with the presence of immune escape mechanisms in ovarian cancers, according to researchers.
The OS benefit of carboplatin desensitization was limited to the subgroup of women with recurrent ovarian cancer without deleterious germline BRCA1/2 mutations.
Researchers found that adjuvant chemoradiation therapy was preferable over adjuvant radiation therapy alone for squamous cell carcinoma of the vulva.
Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.
Tumor response rates were higher in patients with platinum-sensitive recurrent ovarian cancers, according to researchers
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
Black women with locally advanced cervical cancer are significantly less likely to receive brachytherapy compared with non-black women with this disease.
In the QUADRA trial patients with low baseline platelet count or low body weight were more likely to experience grade 3/4 adverse events.